Idexx Laboratories (IDXX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$670.71-3.99%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · IDXX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 33.5% |
| Our one-year growth estimate | diamond | 9.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 24.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 18 industry peers · Company calendar date is not available
IDXX — President transition
Dated 2026-03-26
Executive Vice President, Global Strategy and Commercial — Nimrata Hunt, PhD: Dr. Nimrata Hunt is departing from her role with significant severance benefits.
Why it matters: Management said U.S. recurring sales outpaced sector growth in Q2. Continued gains would support the case for strong customer demand.
Supportive ifU.S. CAG Diagnostics recurring revenue grows at least 10% year over year and remains above the sector growth level.
Worry ifU.S. recurring revenue growth falls below 8%, or IDEXX reports it no longer outpaces sector growth.
Why it matters: IDEXX raised its margin outlook after Q2. Meeting the range would show that sales gains and cost controls offset added spending.
Supportive ifFull-year 2026 operating margin is at least 32.3%, within or above the raised range of 32.3% to 32.5%.
Worry ifFull-year margin falls below 32.3%, or management lowers the margin range.
Why it matters: This is the clearest test of IDEXX’s main growth engine. Q2 organic growth was 10%, and 2026 guidance is 9.5% to 10.7%.
Supportive ifQ3 CAG Diagnostics recurring revenue organic growth is at least 10%. Reported results are within or above the 2026 guidance range of 10.1% to 11.3%.
Worry ifQ3 organic growth falls below 9.5%, or management cuts the 2026 recurring revenue growth range.
Why it matters: The report can show whether IDEXX keeps its raised 2026 targets. It can also test whether profit growth keeps pace with sales.
Watch forIDEXX keeps or raises its 2026 revenue range of $4,700 million to $4,745 million and EPS range of $14.69 to $14.94.
Also watch forIDEXX cuts either 2026 range, or Q3 results miss the raised outlook for revenue or EPS.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$136 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $316 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,417 loss on $10,000 · 34.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.